Table 2 Outcomes of febrile neutropenia episodes in patients with neuroblastoma compared to those with other underlying cancer diagnoses.

From: High frequency of viridians group streptococci bacteremia in pediatric neuroblastoma high-risk patients during induction chemotherapy

 

Total n = 667 (%)

NB N = 82 (%)

ALL N = 202 (%)

AML N = 82 (%)

Solid tumor N = 147 (%)

SCT N = 154 (%)

p-value

BSI

145 (21.7%)

22 (26.8%)

39 (19.3%)

29 (35.4%)

23 (15.6%)

32 (20.8%)

 

Crude OR (95%CI)

 

1

0.65 (0.36–1.19)

1.49 (0.77–2.91)

0.51 (0.26–0.98)*

0.72 (0.38–1.34)

0.008

Adjusted OR (95%CI)

 

1

0.71 (0.38–1.34)

1.54 (0.77–3.1)

0.57 (0.29–1.11)

0.71 (0.37–1.37)

0.021

VGS

37 (5.5%)

10 (12.2%)

9 (4.5%)

8 (9.8%)

3 (2%)

7 (4.5%)

 

Crude OR (95%CI)

 

1

0.34 (0.13–0.86)*

0.78 (0.29–2.08)

0.15 (0.04–0.56)*

0.34 (0.13–0.94)*

0.016

Adjusted OR (95%CI)

 

1

0.43 (0.16–1.13)

1 (0.35–2.83)

0.17 (0.04–0.64)*

0.41 (0.14–1.18)

0.031

GP

74 (11.1%)

14 (17.1%)

21 (10.4%)

14 (17.1%)

5 (3.4%)

20 (13%)

 

Crude OR (95%CI)

 

1

0.56 (0.27–1.17)

1 (0.44–2.26)

0.17 (0.06–0.49)*

0.73 (0.35–1.52)

0.01

Adjusted OR (95%CI)

 

1

0.65 (0.30–1.38)

1.09 (0.47–2.53)

0.19 (0.07–0.55)*

0.75 (0.35–1.64)

0.018

GN

56 (8.4%)

7 (8.5%)

14 (6.9%)

13 (15.9%)

10 (6.8%)

12 (7.8%)

 

Crude OR (95%CI)

 

1

0.8 (0.31–2.06)

2.02 (0.76–2.35)

0.78 (0.29–2.14)

0.91 (0.34–2.4)

0.153

Adjusted OR (95%CI)

 

1

0.99 (0.37–2.65)

2.45 (0.88–2.796)

0.99 (0.35–2.79)

1.08 (0.39–3)

0.19

PICU

88 (13.2%)

14 (17.1%)

21 (10.4%)

14 (17.1%)

10 (6.8%)

29 (18.8%)

 

Crude OR (95%CI)

 

1

0.56 (0.27–1.17)

1 (0.44–2.26)

0.36 (0.15–0.84)*

1.13 (0.56–2.28)

0.015

Adjusted OR (95%CI)

 

1

0.56 (0.26–1.20)

0.98 (0.41–2.31)

0.38 (0.16–0.93)*

1.14 (0.54–0.93)

0.032

Mortality

15 (2.2%)

1 (1.2%)

1 (0.5%)

3 (3.7%)

2 (1.4%)

8 (5.2%)

 

Crude OR (95%CI)

 

1

0.40 (0.03–6.52)

3.08 (0.31–30.2)

1.12 (0.1–12.5)

4.44 (0.55–36.12)

0.091

Adjusted OR (95%CI)

 

1

0.28 (0.02–4.82)

1.81 (0.17–19.39)

1.06 (0.09–12.65)

2.41 (0.27–21.39)

0.33

  1. *p-value < 0.05.
  2. Odds ratio was adjusted for chemotherapy in the last 2 weeks or during the febrile neutropenia episode, fever, gastrointestinal symptoms, and mucositis.
  3. NB neuroblastoma, ALL acute lymphoblastic leukemia, AML acute myelogenous leukemia, SCT stem cell transplant recipients, BSI bloodstream infection, GP gram positive, GN gram negative, PICU pediatric intensive care unit.
Back to article page